<p>Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.</p>

Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.

Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback

Sign up to save your podcasts

Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback

Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback

More shows like Industry Focus

Motley Fool Money

Motley Fool Answers

Rule Breaker Investing

MarketFoolery